Second-Half Comeback Predicted for 2022 Big Pharma Investment

Experts at PwC are confident that a disappointing first half of 2022 in the pharmaceutical and life sciences industries will give way to an end-of-year “flurry of deals.” Big pharma firms, particularly those flush with extra funds derived from wise COVID-19 market investment, are ready to spend, the professional prognosticators report—and the need for new assets to fill lacking pipelines will buoy the flagging market...